A study published in the Journal of the American College of Cardiology has provided more evidence that the muscle weakness experienced by significant numbers of people taking statins, is at least in part, due to decreases in CoQ10.
Statins act on the mevalonate pathway and hence reduce the availability of CoQ10. CoQ10 is of course, a vital component of energy production and a frontline antioxidant. The recent study found that this reduction in CoQ10 (caused by the statin) was accompanied by a compromised energetic state within the muscle.
The prevalence of muscle pain in statin users ranges from 10 percent in patients who are sedentary to 75 percent in athletes.
The researchers also found quiet dramatic changes in blood glucose and insulin levels. These results are displayed in the graph below (taken directly from the study). The patients (those receiving the statin) showed significant increases in blood glucose and insulin resistance. It has been known for some time that statins cause type 2 diabetes, but this fact is often played down by those who support the use of statins. This study has shown, quite clearly, the impact that statins have on blood glucose.
Type 2 diabetes is becoming a worldwide epidemic. According to the CDC, current trends predict that 1 in 3 American adults could have diabetes by 2050. What a perfect situation for the pharmaceutical companies – the tens of millions of people on statins leading to a huge global market for diabetes medications!
Larsen, S et al. Simvastatin Effects on Skeletal Muscle. J Am Coll Cardiol. 2013; 61:44-53.
Meador, B.M. and Huey K.A. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010; 42 469-479.